Amneal secured FDA approval for epinephrine injection USP, 1 mg/mL, in 1 mL single-dose and 30 mL multi-dose vials for institutional use, adding a new supplier to a high-velocity hospital essential. The products cover emergency treatment of anaphylaxis and pressor support in adult septic shock. IQVIA estimates U.S. sales for these vial presentations at approximately $118 million over the past year, underscoring steady demand across emergency departments, perioperative settings, and infusion centers.
The move extends Amneal’s sterile injectables push into a category that has seen recurring supply fragility. Epinephrine vials are ubiquitous across crash carts and allergy clinics, but procurement has been complicated by periodic backorders, shifting NDCs, and preference swings between single- and multi-dose formats due to infection control policies and waste considerations. By offering both presentations, Amneal is positioning for formulary flexibility—single-dose for code carts and procedural areas where contamination risk and dating rules drive practice, and multi-dose for pharmacy compounding, allergy testing/treatment, and drip preparation where throughput and cost containment matter.
For research sites, trial units, and infusion centers, an additional source of 1 mg/mL epinephrine lowers operational risk tied to protocol-required emergency readiness for biologics, cell/gene therapies, and contrast or infusion-related reactions. Site initiation often hinges on documented access to rescue meds; reliable vial supply reduces start-up friction, supports decentralized and community-based enrollment where pharmacy infrastructure is lighter, and minimizes reliance on 503B compounded alternatives when commercial supply tightens. Hospital-based trial operations benefit from simplified crash cart restocking and fewer last-minute product substitutions that trigger retraining and policy amendments.
Procurement dynamics will turn on group purchasing agreements, NDC alignment with automated dispensing cabinets, and whether Amneal follows with ready-to-admin formats that many institutions prefer for code scenarios. The 30 mL multi-dose vial offers an efficiency lever, but facilities will weigh preservative content, beyond-use dating, and infection control policies that have increasingly favored unit-dose in high-acuity areas. Competition among multisource suppliers remains active; incremental share will likely come from reliability, fill-finish capacity, and the ability to stay off the FDA Drug Shortages list rather than headline price alone.
The forward watchlist is straightforward: sustained production performance, any expansion into prefilled or diluted concentrations, and early GPO wins that signal formulary traction. With sterile injectables still vulnerable to recalls and capacity bottlenecks, execution at the plant level will be decisive. If Amneal converts approval into dependable supply, sites and sponsors should see fewer protocol deviations tied to emergency drug substitutions and smoother activation timelines. If not, hospitals will continue to diversify vendors and maintain contingency ordering with 503B compounders. Either way, a new FDA-cleared entrant should add modest stability to a staple category that quietly underpins trial safety and continuity.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Key Clinical Advances: New Epinephrine Approval and Seizure Treatment Data - Nova Health Express
9 months ago[…] a new epinephrine product developed by Amneal for use in U.S. hospitals. 🔗 Read more: FDA Approved Amneal’s New Epinephrine for U.S. […]